# EDGAR Filing Document

**Accession Number:** 0001579982
**File Stem:** 0000940400-26-025086
**Filing Date:** 2026-6
**Character Count:** 24094
**Document Hash:** a60ff4b2ed203191ba662086d51faef8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000940400-26-025086.hdr.sgml**: 20260623

**ACCESSION NUMBER**: 0000940400-26-025086

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260430

**FILED AS OF DATE**: 20260623

**DATE AS OF CHANGE**: 20260623

**PERIOD START**: 20260731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARK ETF Trust
- **CENTRAL INDEX KEY:** 0001579982

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-22883
- **FILM NUMBER:** 261109975

**BUSINESS ADDRESS:**
- **STREET 1:** 155 WEST 19TH STREET, FIFTH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011
- **BUSINESS PHONE:** 212.426.7040

**MAIL ADDRESS:**
- **STREET 1:** 155 WEST 19TH STREET, FIFTH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ark ETF Trust
- **DATE OF NAME CHANGE:** 20130624

## Series and Classes Contracts Data

### ARK Genomic Revolution ETF (Series ID: S000042975)

| Class ID   | Class Name                 | Ticker Symbol   |
|:---|:---|:---|
| C000133119 | ARK Genomic Revolution ETF | ARKG            |

## Nport-Ex

Schedule of Investments

ARK Genomic Revolution ETF

April 30, 2026 (Unaudited)

---

| | | |
|:---|:---|:---|
| **Investments** | **Shares** | **Value** |
| **COMMON STOCKS–99.6%** | | |
| **Biotechnology - 57.0%** | **Biotechnology - 57.0%** | **Biotechnology - 57.0%** |
| Absci Corp.\*<sup>†(a)</sup> | 11876202 | $59084105 |
| Arcturus Therapeutics Holdings, Inc.\*<sup>†(a)</sup> | 2809043 | 24213950 |
| Beam Therapeutics, Inc.\* | 2212153 | 67094600 |
| BioNTech SE (Germany)\*<sup>(b)</sup> | 126929 | 13130805 |
| CareDx, Inc.\* | 2009757 | 41823043 |
| Compass Pathways PLC (United Kingdom)\*<sup>(b)</sup> | 3316076 | 30043649 |
| CRISPR Therapeutics AG (Switzerland)\*<sup>(a)</sup> | 2103707 | 110108024 |
| Generate BioMedicines, Inc.\* | 503531 | 6359597 |
| Intellia Therapeutics, Inc.\*<sup>(a)</sup> | 3498399 | 47158418 |
| Ionis Pharmaceuticals, Inc.\* | 288230 | 21548075 |
| Natera, Inc.\* | 243718 | 50244903 |
| Nurix Therapeutics, Inc.\* | 1723734 | 28786358 |
| Prime Medicine, Inc.\* | 4925864 | 17462188 |
| Recursion Pharmaceuticals, Inc., Class A\*<sup>(a)</sup> | 12549240 | 43420370 |
| Twist Bioscience Corp.\* | 1900539 | 111086505 |
| Veracyte, Inc.\* | 999975 | 32919177 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Biotechnology |  | 704483767 |
| **Electronic Equipment, Instruments & Components - 1.1%** |  |  |
| 908 Devices, Inc.\*<sup>†</sup> | 1952552 | 13335930 |
| **Health Care Equipment & Supplies - 3.1%** |  |  |
| Butterfly Network, Inc.\*<sup>(a)</sup> | 4889029 | 23418449 |
| Cerus Corp.\* | 7450534 | 15124584 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Health Care Equipment & Supplies |  | 38543033 |
| **Health Care Providers & Services - 5.6%** |  |  |
| GeneDx Holdings Corp.\* | 401292 | 25237254 |
| Guardant Health, Inc.\* | 496000 | 43191680 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Health Care Providers & Services |  | 68428934 |
| **Health Care Technology - 2.0%** |  |  |
| Schrodinger, Inc.\* | 2093199 | 25034660 |
| **Life Sciences Tools & Services - 28.4%** |  |  |
| 10X Genomics, Inc., Class A\* | 3232541 | 71277529 |
| Adaptive Biotechnologies Corp.\* | 2123561 | 29942210 |
| Alamar Biosciences, Inc.\*<sup>(a)</sup> | 596585 | 14938489 |
| Illumina, Inc.\* | 392835 | 49787908 |
| Pacific Biosciences of California, Inc.\* | 10964895 | 17434183 |
| Personalis, Inc.\*<sup>†</sup> | 8017242 | 44255176 |
| Quantum-Si, Inc.\*<sup>(a)</sup> | 6928343 | 6793933 |
| Tempus AI, Inc.\*<sup>(a)</sup> | 2098455 | 116422283 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Life Sciences Tools & Services |  | 350851711 |
| **Pharmaceuticals - 2.4%** |  |  |
| AtaiBeckley, Inc. (Germany)\* | 4382604 | 18231633 |
| Eli Lilly & Co. | 12571 | 11748856 |
| Total Pharmaceuticals |  | 29980489 |
| **Total Common Stocks** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Cost $2,614,311,648) |  | 1230658524 |

---

---

| | | |
|:---|:---|:---|
| **Investments** | **Shares** | **Value** |
| **MONEY MARKET FUND–0.1%** |  |  |
| Goldman Sachs Financial Square Treasury Obligations Fund, 3.54% <sup>(c)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Cost $1,581,573) | 1581573 | $1581573 |
| **Total Investments–99.7%** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Cost $2,615,893,221) |  | **1232240097** |
| Other Assets in Excess of Liabilities–0.3% |  | 3632208 |
| **Net Assets–100.0%** |  | $**1235872305** |

---

---

| | |
|:---|:---|
| (a) | All or a portion of the security was on loan. The aggregate market value of the securities on loan was $157,344,717; total market value of the collateral held by the fund was $149,290,355.The total market value of the collateral includes non-cash U.S. Treasury securities collateral having a value of $149,290,355. |
| † | Affiliated security |
| \* | Non-income producing security |
| (b) | American Depositary Receipt |
| (c) | Rate shown represents annualized 7-day yield as of April 30, 2026. |

---

Schedule of Investments (continued)

ARK Genomic Revolution ETF

April 30, 2026 (Unaudited)

**Affiliated Issuer Transactions**

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities, or a company that is under common ownership or control. Period-to-date transactions with companies which are or were affiliates are as follows:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Value ($) at 7/31/2025<sup>(a)</sup>** | **Purchases Cost ($)** | **Sales Proceeds ($)** | **Net Realized<br> Gain/(Loss) on<br> investments in <br> affiliated<br> securities ($)** | **Net Change in<br> Unrealized<br> Appreciation<br> (Depreciation)<br> on investments<br> in affiliated<br> securities ($)** | **Net Change in<br> Unrealized<br> Appreciation<br> (Depreciation)<br> on investments<br> in non-affiliated<br> securities ($)** | **Affiliated Dividend<br> Income<br> ($)** | **Capital Gain<br> Distributions ($)** | **Number of<br> Shares at<br> 4/30/2026** | **Value ($) at 4/30/2026<sup>(a)</sup>** |
| **Common Stocks — 11.4%** | **Common Stocks — 11.4%** | **Common Stocks — 11.4%** | **Common Stocks — 11.4%** | **Common Stocks — 11.4%** | **Common Stocks — 11.4%** | | | | | |
| Biotechnology — 6.7% | Biotechnology — 6.7% | Biotechnology — 6.7% | Biotechnology — 6.7% | Biotechnology — 6.7% | Biotechnology — 6.7% | Biotechnology — 6.7% | Biotechnology — 6.7% | Biotechnology — 6.7% | Biotechnology — 6.7% |  |
| Absci Corp. |  |  |  |  |  |  |  |  |  |  |
|  | 33212741 | 49408090 | (45558687) | 771774 | 21250187 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;– | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;– |  | 11876202 | 59084105 |
| Arcturus Therapeutics Holdings, Inc. |  |  |  |  |  |  |  |  |  |  |
|  | 20607391 | 41450786 | (28007344) | 556445 | (10393328) |  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;– | 2809043 | 24213950 |
| Electronic Equipment, Instruments & Components — 1.1% |  |  |  |  |  |  |  |  |  |  |
| 908 Devices, Inc. |  |  |  |  |  |  |  |  |  |  |
|  | 14371630 | 16218179 | (17431703) | (10244915) | 10422739 |  |  |  | 1952552 | 13335930 |
| Life Sciences Tools & Services — 3.6% |  |  |  |  |  |  |  |  |  |  |
| Personalis, Inc. |  |  |  |  |  |  |  |  |  |  |
|  | 38378556 | 87151810 | (81311198) | (4038234) | 4074242 | – | – | – | 8017242 | 44255176 |
|  | $106570318 | $194228865 | $(172308932) | $(12954930) | $25353840 | $– | $– | $– | 24655039 | $140889161 |

---

(a) The fair value and number of shares of securities are only displayed at the beginning and end of
 each reporting period when such securities were considered an affiliate as of each date. Refer to the Schedule of Investments for
 view the fair value and number of shares as of April 30, 2026.

**Fair Value Measurement**<br>The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund's own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

• **Level 1** — Quoted prices in active markets for identical assets.

• **Level 2** — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

• **Level 3** — Significant unobservable inputs (including each Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the valuations as of April 30, 2026, based upon the three levels defined above:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **ARK Genomic Revolution ETF** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Assets** | | | | |
| Common Stocks<sup>‡</sup> | $1230658524 | $– | $– | $1230658524 |
| Money Market Fund | 1581573 | – | – | 1581573 |
| Total | $1232240097 | $– | $– | $1232240097 |

---

‡ Please refer to the Schedule of Investments to view securities segregated by industry type.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** ARK ETF Trust

- **b. Investment Company Act file number:** 811-22883

- **c. CIK number of Registrant:** 0001579982

- **d. LEI of Registrant:** 2549000Z0EWMH3U0CQ16

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 200 Central Avenue

  - **City:** St. Petersburg

  - **State:** FL

  - **Foreign country:** US

  - **Zip / Postal Code:** 33701

  - **Telephone number:** 727-810-8160

**Item A.2. Information about the Series.**

- **a. Name of Series:** ARK Genomic Revolution ETF

- **b. EDGAR series identifier (if any):** S000042975

- **c. LEI of Series:** 254900EYF7TANB19PE71

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-07-31

- **b. Date as of which information is reported:** 2026-04-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1236561022.30

**Total Liabilities:** $688716.98

**Net Assets:** $1235872305.32

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000133119 | -1.48%               | -11.69%              | 12.96%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-6173822.64             | $-9938853.25                               |
| Month 2  | $-36182658.53            | $-103824596.90                             |
| Month 3  | $-21364864.55            | $155860720.60                              |

### Schedule of Portfolio Investments

| Name                                                     | Title                                                    | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| PRIME MEDICINE INC                                       | PRIME MEDICINE INC COM                                   | CUSIP: 74168J101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   4925864 | NS      | $17462187.88  | 1.41%             |  |  |  | No            |                  1 | On Loan: No      |
| ABSCI CORP                                               | ABSCI CORP COM                                           | CUSIP: 00091E109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |  11876202 | NS      | $59084104.95  | 4.78%             |  |  |  | No            |                  1 | On Loan: —       |
| VERACYTE INC                                             | VERACYTE INC COM                                         | CUSIP: 92337F107<br>LEI: 529900ESWZRHXOW27Z37 | Long             | EC               | CORP              | US        |    999975 | NS      | $32919177.00  | 2.66%             |  |  |  | No            |                  1 | On Loan: No      |
| ADAPTIVE BIOTECHNOLOGIES CORP                            | ADAPTIVE BIOTECHNOLOGIES CORP COM                        | CUSIP: 00650F109<br>LEI: 549300ZTF7OT1FW66Q96 | Long             | EC               | CORP              | US        |   2123561 | NS      | $29942210.10  | 2.42%             |  |  |  | No            |                  1 | On Loan: No      |
| NATERA INC                                               | NATERA INC COM                                           | CUSIP: 632307104<br>LEI: 529900CQ3OZ0A0VYVU59 | Long             | EC               | CORP              | US        |    243718 | NS      | $50244902.88  | 4.07%             |  |  |  | No            |                  1 | On Loan: No      |
| ARCTURUS THERAPEUTICS HOLDINGS INC                       | ARCTURUS THERAPEUTICS HOLDINGS INC COM                   | CUSIP: 03969T109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2809043 | NS      | $24213950.66  | 1.96%             |  |  |  | No            |                  1 | On Loan: —       |
| NURIX THERAPEUTICS INC                                   | NURIX THERAPEUTICS INC COM                               | CUSIP: 67080M103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1723734 | NS      | $28786357.80  | 2.33%             |  |  |  | No            |                  1 | On Loan: No      |
| QUANTUM-SI INC                                           | QUANTUM-SI INC COM CL A                                  | CUSIP: 74765K105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   6928343 | NS      | $6793933.15   | 0.55%             |  |  |  | No            |                  1 | On Loan: —       |
| SCHRODINGER INC                                          | SCHRODINGER INC COM                                      | CUSIP: 80810D103<br>LEI: 984500044BAE4791E559 | Long             | EC               | CORP              | US        |   2093199 | NS      | $25034660.04  | 2.03%             |  |  |  | No            |                  1 | On Loan: No      |
| CAREDX INC                                               | CAREDX INC COM                                           | CUSIP: 14167L103<br>LEI: 549300NQOFKL9NON0U06 | Long             | EC               | CORP              | US        |   2009757 | NS      | $41823043.17  | 3.38%             |  |  |  | No            |                  1 | On Loan: No      |
| ATAIBECKLEY INC                                          | ATAIBECKLEY INC COM SHS                                  | CUSIP: 04650F101<br>LEI: 529900HOVZ0MXOBQ5Y47 | Long             | EC               | CORP              | US        |   4382604 | NS      | $18231632.64  | 1.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Goldman Sachs Financial Square Treasury Obligations Fund | Goldman Sachs Financial Square Treasury Obligations Fund | CUSIP: 000000000<br>LEI: 549300C0TCI4VJPGCS21 | Long             | STIV             | RF                | US        |   1581573 | NS      | $1581572.56   | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| COMPASS PATHWAYS PLC                                     | COMPASS PATHWAYS PLC SPONSORED ADS                       | CUSIP: 20451W101<br>LEI: 213800N7CUZIC6QSTZ31 | Long             | EC               | CORP              | GB        |   3316076 | NS      | $30043648.56  | 2.43%             |  |  |  | No            |                  1 | On Loan: No      |
| IONIS PHARMACEUTICALS INC                                | IONIS PHARMACEUTICALS INC COM                            | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |    288230 | NS      | $21548074.80  | 1.74%             |  |  |  | No            |                  1 | On Loan: No      |
| ALAMAR BIOSCIENCES INC                                   | ALAMAR BIOSCIENCES INC COMMON STOCK                      | CUSIP: 010911105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    596585 | NS      | $14938488.40  | 1.21%             |  |  |  | No            |                  1 | On Loan: —       |
| BEAM THERAPEUTICS INC                                    | BEAM THERAPEUTICS INC COM                                | CUSIP: 07373V105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2212153 | NS      | $67094600.49  | 5.43%             |  |  |  | No            |                  1 | On Loan: No      |
| GUARDANT HEALTH INC                                      | GUARDANT HEALTH INC COM                                  | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |    496000 | NS      | $43191680.00  | 3.49%             |  |  |  | No            |                  1 | On Loan: No      |
| GENERATE BIOMEDICINES INC                                | GENERATE BIOMEDICINES INC COM SHS                        | CUSIP: 370920100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    503531 | NS      | $6359596.53   | 0.51%             |  |  |  | No            |                  1 | On Loan: No      |
| TWIST BIOSCIENCE CORP                                    | TWIST BIOSCIENCE CORP COM                                | CUSIP: 90184D100<br>LEI: 549300T23BL59LCOH584 | Long             | EC               | CORP              | US        |   1900539 | NS      | $111086504.55 | 8.99%             |  |  |  | No            |                  1 | On Loan: No      |
| 10X GENOMICS INC                                         | 10X GENOMICS INC CL A COM                                | CUSIP: 88025U109<br>LEI: 5493003Z6741WNLG7H43 | Long             | EC               | CORP              | US        |   3232541 | NS      | $71277529.05  | 5.77%             |  |  |  | No            |                  1 | On Loan: No      |
| PACIFIC BIOSCIENCES OF CALIFORNIA INC                    | PACIFIC BIOSCIENCES OF CALIFORNIA INC COM                | CUSIP: 69404D108<br>LEI: 529900F1BWRE1M0KZN89 | Long             | EC               | CORP              | US        |  10964895 | NS      | $17434183.05  | 1.41%             |  |  |  | No            |                  1 | On Loan: No      |
| 908 DEVICES INC                                          | 908 DEVICES INC COM                                      | CUSIP: 65443P102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1952552 | NS      | $13335930.16  | 1.08%             |  |  |  | No            |                  1 | On Loan: No      |
| CRISPR THERAPEUTICS AG                                   | CRISPR THERAPEUTICS AG NAMEN AKT                         | CUSIP: 000000000<br>LEI: 506700O6IRRIQLT3W370 | Long             | EC               | CORP              | CH        |   2103707 | NS      | $110108024.38 | 8.91%             |  |  |  | No            |                  1 | On Loan: —       |
| PERSONALIS INC                                           | PERSONALIS INC COM                                       | CUSIP: 71535D106<br>LEI: 549300EZ2NYFK7H0US48 | Long             | EC               | CORP              | US        |   8017242 | NS      | $44255175.84  | 3.58%             |  |  |  | No            |                  1 | On Loan: No      |
| GENEDX HOLDINGS CORP                                     | GENEDX HOLDINGS CORP COM CL A                            | CUSIP: 81663L200<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    401292 | NS      | $25237253.88  | 2.04%             |  |  |  | No            |                  1 | On Loan: No      |
| CERUS CORP                                               | CERUS CORP COM                                           | CUSIP: 157085101<br>LEI: 254900BIEY9XIDA04Q21 | Long             | EC               | CORP              | US        |   7450534 | NS      | $15124584.02  | 1.22%             |  |  |  | No            |                  1 | On Loan: No      |
| RECURSION PHARMACEUTICALS INC                            | RECURSION PHARMACEUTICALS INC CL A                       | CUSIP: 75629V104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |  12549240 | NS      | $43420370.40  | 3.51%             |  |  |  | No            |                  1 | On Loan: —       |
| TEMPUS AI INC                                            | TEMPUS AI INC CL A                                       | CUSIP: 88023B103<br>LEI: 2549009LA0KWRAGQBX50 | Long             | EC               | CORP              | US        |   2098455 | NS      | $116422283.40 | 9.42%             |  |  |  | No            |                  1 | On Loan: —       |
| ELI LILLY & COMPANY                                      | ELI LILLY & COMPANY COM                                  | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |     12571 | NS      | $11748856.60  | 0.95%             |  |  |  | No            |                  1 | On Loan: No      |
| INTELLIA THERAPEUTICS INC                                | INTELLIA THERAPEUTICS INC COM                            | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |   3498399 | NS      | $47158418.52  | 3.82%             |  |  |  | No            |                  1 | On Loan: —       |
| BUTTERFLY NETWORK INC                                    | BUTTERFLY NETWORK INC COM CL A                           | CUSIP: 124155102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   4889029 | NS      | $23418448.91  | 1.89%             |  |  |  | No            |                  1 | On Loan: —       |
| ILLUMINA INC                                             | ILLUMINA INC COM                                         | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |    392835 | NS      | $49787907.90  | 4.03%             |  |  |  | No            |                  1 | On Loan: No      |
| BIONTECH SE                                              | BIONTECH SE SPONSORED ADS                                | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |    126929 | NS      | $13130805.05  | 1.06%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-06-23

**Name of Applicant:** ARK ETF Trust

**Signature:** Bill Cox

**Name of Signer:** Bill Cox

**Title:** Principal Financial Officer